Personalis, Inc.

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and globally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers. It also provides ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and tumor microenvironment. Additionally, Personalis offers NeXT Personal Dx for MRD detection and NeXT Dx, a tumor profiling test used to help select therapy and identify potential clinical trials. The company also performs whole exome and whole genome sequencing for diagnostic companies and research projects.

Personalis, Inc. is listed on the NasdaqGM exchange under the ticker symbol PSNL. Its securities are traded in US Dollars (USD). The company is headquartered in the United States and operates primarily in the US region, though it serves customers globally.

Personalis operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This means the company focuses on developing and providing diagnostic tests and research services, particularly in the field of oncology. Its products and services are used for cancer detection, monitoring, and therapy selection, as well as for translational research and biomarker discovery by pharmaceutical and biopharmaceutical companies.

Personalis's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company's services are used by pharmaceutical firms for translational research, biomarker discovery, development of personalized cancer therapies, and clinical trials. Physicians use Personalis's tests to detect residual or recurrent cancer, monitor response to therapy, and uncover insights for therapy selection. Additionally, the company performs sequencing for diagnostic companies and research projects such as population sequencing initiatives.

Personalis offers several key products: NeXT Personal, a tumor-informed liquid biopsy test for detecting minimal residual disease (MRD), monitoring therapy response and recurrence in solid tumors; ImmunoID NeXT, a tissue-based service combining whole exome and whole transcriptome sequencing with advanced analytics; NeXT Personal Dx, a tumor-informed liquid biopsy test for MRD detection; and NeXT Dx, a tumor profiling test for therapy selection and clinical trial identification. The company also provides whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies, as well as whole genome sequencing for research projects.